Small molecule antiviral drug treatment for human papillomavirus infections

1. A compound that covalently attaches to an HPV E6 protein within an alpha helix binding pocket in the HPV E6 protein, thereby preventing binding of another protein in said binding pocket, wherein said compound has the structure of:

wherein

X 2 is N, S or C;

R 10 is H, CH 3 , CF 3 , OCH 3 , OCF 3 , CN or halo;

R 11 is H or OCH 3 ;

R 42 and R 48 together with the atoms to which they are bound form a 10 membered heteroaryl; and

R 31 is selected from the group consisting of —CR 51 ═CH 2 , —CH═CHCH 2 N(CH 3 ) 2 and —CH═CHCH 3 , wherein R 51 is H or F.

2. A formulation comprising the compound of claim 1 and a pharmaceutically-acceptable adjuvant, diluent or carrier.

3. The formulation of claim 2 provided in a nanoparticle for targeted delivery.

4. A method for treating an HPV infection, the method comprising the step of administering a formulation according to claim 2 to a subject in need of treating the HPV infection.

5. The method of claim 4 , wherein said formulation is administered orally, transdermally, topically, subcutaneously, intramuscularly, or intravenously.

6. The method of claim 4 , wherein the formulation is formulated for topical application to the cervix, anus, or pharynx.

7. The method of claim 5 , wherein said formulation is administered transdermally.

8. The method of claim 4 , wherein said formulation is a time-release formulation.

9. The formulation of claim 2 , wherein the formulation further comprises a compound selected from the group consisting of fatty acids, glucose, amino acids, cholesterol, lipids, glycosides, alkaloids, and natural phenols.

10. The compound of claim 1 having the structure of

wherein

R 31 is —CH═CH 2 ,

X 2 is S; and

R 42 and R 48 together with the atoms to which they are bound form a 10 membered heteroaryl.